BioIVT

#Biospecimens play an indispensable role in the rapidly evolving field of #WeightLoss #DrugDevelopment. Researchers rely on these samples to understand the underlying mechanisms of obesity and to develop effective treatments. Explore the critical components of biospecimen collection necessary for advancing weight loss drugs: https://lnkd.in/gWMivys8 #ObesityResearch #MetabolicDisease #HealthcareInnovation

We’ve expanded our #CellandGeneTherapy supporting product portfolio to include the new LEUKOMAX XL Fresh #Leukopaks! With a fill volume of approximately 250 mL, you can quickly and efficiently obtain a larger quantity of human-derived cellular starting material to support downstream development, featuring: - More #ImmuneCells (IC) per volume - Large global characterized donor network - Comprehensive donor screening and infectious disease panel - Options for #PBMCs or IC subset isolations Learn more or request a quote: https://lnkd.in/eUQMQVjD #CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies

Get answers to frequently asked questions about working with plateable #hepatocytes as BioIVT expert Halee McElhaney discusses common reasons why hepatocyte plating fails and describes helpful techniques that will improve the performance of your plated hepatocytes in your in vitro assays: https://hubs.ly/Q02MvL9c0 #ADME #DMPK #DrugMetabolism #DrugInteractions

We are a company with a common purpose – to improve the lives of people around the globe by enabling smarter science. At BioIVT, we are proud to deliver personalized biospecimen solutions and research services to life science and diagnostic organizations that are enhancing and extending lives through medical breakthroughs: https://hubs.ly/Q02M1cDm0 #ELEVATINGscience #Biospecimens #SmarterScience

The accuracy of your research depends on the quality and relevancy of your test system. Just because two #biospecimens seem like they should be the same, it doesn’t mean they are. According to a US survey of National Cancer Institute (NCI) funded cancer researchers, lack of quality biospecimens resulted in 60% of researchers questioning their findings and 81% limiting the scope of their work. What could it be costing you and how can you avoid these issues? Learn more: https://lnkd.in/dZjVMrmv

BioIVT is pleased to announce it has acquired ZenBio, a distinguished industry leader in advanced cell products and services. Together, BioIVT and ZenBio will offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for #pharma and #cosmetics companies. Based in Durham, North Carolina, ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise and flexibility to meet researchers’ needs. Both BioIVT and ZenBio share a vision of providing top-quality biospecimens and biotechnology services to support scientific discovery and innovation. Learn more about the acquisition ➡️ https://hubs.ly/Q02M1bZs0 #DrugDiscovery #PreclinicalResearch #SkinTissue #Pharmaceuticals

Did you miss the #ISCT2024 conference roundtable on strategies for ensuring your raw and ancillary material supply chain during #CellandGeneTherapy development? Read a recap of the discussion from our CGT Senior Product Manager, Jordan Hunter: https://hubs.ly/Q02LP1WL0 Main discussion points of the roundtable included: • Identifying key risks that impact supply chain and manufacturing processes. • The essential components of a robust regulatory and manufacturing framework. • Identifying key attributes for cellular starting material providers. Read the recap now: https://hubs.ly/Q02LP1WL0 #CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies #RegulatoryCompliance

With over 25 years of expertise in providing human and animal #hepatocytes, BioIVT is the go-to for all your hepatic needs: https://hubs.ly/Q02LHTq80. Check out our video to learn more! #ADME #drugmetabolism #druginteractions #toxicology

#CARTcell therapy has proven effective in treating relapsed blood #cancers, yet producing large quantities of quality cells continues to be a challenge. A recent study explored new methods to systematically improve the process of making CAR-T cells, leading to better and more efficient production of these important cancer-fighting cells. We're proud to share that primary #Tcells used in these studies were partially obtained from #leukopaks provided by BioIVT. The leukopaks were delivered the same day as the collection, allowing them to be immediately processed upon delivery to isolate the CD3+ T cells. Explore the full study: https://hubs.ly/Q02KWPN10 #CancerResearch #CARTCells #CellTherapy #ElevatingScience